• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.

Article similar to the Article

Researcher similar to the Article

Patent similar to the Article

Research Project similar to the Article

Author(J-GLOBAL estimation)

Article citing the Article

Patent citing the Article

Art
J-GLOBAL ID:202002239465541310   Reference number:20A1717142

Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese

過体重および肥満における直接作用経口抗凝固薬(DOAC)の有効性と安全性【JST・京大機械翻訳】
Clips

Reference (31)

  • T. Kelly, W. Yang, C.-S. Chen, K. Reynolds, J. He, "Global burden of obesity in 2005 and projections to 2030," International Journal of Obesity, vol. 32, no. 9, pp. 1431-1437, 2008.
  • M. T. Severinsen, S. R. Kristensen, S. P. Johnsen, C. Dethlefsen, A. Tjønneland, K. Overvad, "Anthropometry, body fat, and venous thromboembolism," Circulation, vol. 120, no. 19, pp. 1850-1857, 2009.
  • M. Abdollahi, M. Cushman, F. Rosendaal, "Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use," Thrombosis and Haemostasis, vol. 89, no. 3, pp. 493-498, 2003.
  • K. H. Borch, S. K. Braekkan, E. B. Mathiesen et al., "Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromsø study," Journal of Thrombosis and Haemostasis, vol. 7, no. 5, pp. 739-745, 2009.
  • P. L. Lutsey, B. A. Virnig, S. B. Durham et al., "Correlates and consequences of venous thromboembolism: the Iowa Women's Health Study," American Journal of Public Health, vol. 100, no. 8, pp. 1506-1513, 2010.
  • T. van der Hulle, J. Kooiman, P. L. den Exter, O. M. Dekkers, F. A. Klok, M. V. Huisman, "Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis," Journal of Thrombosis and Haemostasis, vol. 12, no. 3, pp. 320-328, 2014.
  • J. Domienik-Karlowicz, P. Pruszczyk, "The use of anticoagulants in morbidly obese patients," Journal of Cardiology, vol. 23, pp. 12-16, 2016.
  • G. Agnelli, H. R. Buller, A. Cohen et al., "Oral apixaban for the treatment of acute venous thromboembolism," New England Journal of Medicine, vol. 369, no. 9, pp. 799-808, 2013.
  • S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., "Dabigatran versus warfarin in patients with atrial fibrillation," New England Journal of Medicine, vol. 361, no. 12, pp. 1139-1151, 2009.
  • V. T. E. I. Hokusai, H. R. Buller, H. Decousus et al., "Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism," New England Journal of Medicine, vol. 369, pp. 1406-1415, 2013.
  • E. Investigators, R. Bauersachs, S. D. Berkowitz et al., "Oral rivaroxaban for symptomatic venous thromboembolism," New England Journal of Medicine, vol. 363, pp. 2499-2510, 2010.
  • C. B. Granger, J. H. Alexander, J. J. V. McMurray et al., "Apixaban versus warfarin in patients with atrial fibrillation," New England Journal of Medicine, vol. 365, no. 11, pp. 981-992, 2011.
  • M. R. Patel, K. W. Mahaffey, J. Garg et al., "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation," New England Journal of Medicine, vol. 365, no. 10, pp. 883-891, 2011.
  • R. C. P. Makam, D. C. Hoaglin, D. D. McManus et al., "Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis," PLoS One, vol. 13, no. 5, 2018.
  • R. P. Giugliano, C. T. Ruff, E. Braunwald et al., "Edoxaban versus warfarin in patients with atrial fibrillation," New England Journal of Medicine, vol. 369, no. 22, pp. 2093-2104, 2013.
  • E.-P. Investigators, H. R. Buller, M. H. Prins et al., "Oral rivaroxaban for the treatment of symptomatic pulmonary embolism," New England Journal of Medicine, vol. 366, pp. 1287-1297, 2012.
  • S. Schulman, A. K. Kakkar, S. Z. Goldhaber et al., "Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis," Circulation, vol. 129, no. 7, pp. 764-772, 2014.
  • V. V. Upreti, J. Wang, Y. C. Barrett et al., "Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects," British Journal of Clinical Pharmacology, vol. 76, no. 6, pp. 908-916, 2013.
  • R. Pathak, P. Karmacharya, S. Giri et al., "Meta-analysis on efficacy and safety of new oral anticoagulants for venous thromboembolism prophylaxis in overweight and obese postarthroplasty patients," Blood Coagulation & Fibrinolysis, vol. 26, no. 6, pp. 635-642, 2015.
  • D. Kubitza, M. Becka, M. Zuehlsdorf, W. Mueck, "Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects," The Journal of Clinical Pharmacology, vol. 47, no. 2, pp. 218-226, 2007.

1 to 20 of 31 results
Return to Previous Page